SEP
RVMD icon

Signature Equity Partners’s Revolution Medicines RVMD Stock Holding History

Signature Equity Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31K Hold
7
– – ﹤0.01% 1259
2026
Q1 		$681 Buy
+7
New +$707 ﹤0.01% 1334

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Signature Equity Partners's RVMD Position: Q2 2026 in Review

Signature Equity Partners held its Revolution Medicines (RVMD) position steady in Q2 2026 at 7 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1259.

Signature Equity Partners first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Signature Equity Partners held 7 shares of Revolution Medicines worth $1.31K as of Q2 2026.
  • Signature Equity Partners left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1259 holding.
  • Signature Equity Partners first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.